TLR6: A Potential Drug Target and Biomarker (G10333)

Target Name: TLR6

NCBI ID: G10333

TLR6

TLR6: A Potential Drug Target and Biomarker

Toll-like receptor 6 (TLR6) is a protein that is expressed in many different tissues throughout the body. It is a type of immune receptor that is involved in the innate immune system, which is the body's first line of defense against infection. TLR6 is a critical receptor for recognizing and responding to pathogens, such as bacteria, viruses, and fungi.

One of the things that makes TLR6 an attractive drug target is its location on the body. TLR6 is expressed in many different tissues throughout the body, including the skin, mucous membranes, lungs, heart, and blood vessels. for drugs that can inhibit its activity and reduce inflammation.

In addition to its potential as a drug target, TLR6 is also a potential biomarker for a variety of diseases. For example, TLR6 is often expressed in the inflammatory bowel disease, which is a condition that causes chronic inflammation in the gut. Researchers have been interested in using TLR6 as a biomarker to diagnose and track the progression of this disease.

One of the challenges in studying TLR6 is its complex structure. TLR6 is a transmembrane protein that spans the cell membrane. It consists of a cytoplasmic region, a extracellular region, and a transmembrane region. The cytoplasmic region contains the protein's extracellular domain, which is involved in cell signaling. The extracellular region contains the protein's transmembrane domain, which is responsible for interacting with other molecules on the cell surface.

The structure of TLR6 has led to a lot of research and discussion about its potential drug targets. One of the most promising targets is the protein known as NLRP1. NLRP1 is a small protein that is expressed in many different tissues throughout the body. It is involved in the formation of a protein complex called the inflammasome, which is a key player in the production of inflammatory cytokines.

Research has suggested that TLR6 and NLRP1 may have a direct interaction. Studies have shown that TLR6 can activate NLRP1 and that NLRP1 can be activated by TLR6 in an interacting manner. This suggests that TLR6 and NLRP1 may be a team in the production of inflammatory cytokines.

Another potential drug target for TLR6 is the protein known as NF-kappa1. NF-kappa1 is a cytokine that is involved in cell signaling and growth. It is expressed in many different tissues throughout the body and has been implicated in a variety of diseases, including cancer, fibrosis, and autoimmune diseases.

Research has suggested that TLR6 and NF-kappa1 may have a direct interaction. Studies have shown that TLR6 can activate NF-kappa1 and that NF-kappa1 can be activated by TLR6 in an interacting manner. This suggests that TLR6 and NF-kappa1 may be a team in the production of pro-inflammatory cytokines.

In conclusion, TLR6 is a protein that is involved in the innate immune system and has been identified as a potential drug target and biomarker for a variety of diseases. The structure of TLR6 and its complex interactions with other molecules make it an attractive target for the development of new therapies. Further research is needed to fully understand the role of TLR6 in the immune system and to develop effective treatments.

Protein Name: Toll Like Receptor 6

Functions: Participates in the innate immune response to Gram-positive bacteria and fungi. Specifically recognizes diacylated and, to a lesser extent, triacylated lipopeptides (PubMed:20037584). In response to diacylated lipopeptides, forms the activation cluster TLR2:TLR6:CD14:CD36, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR2 (PubMed:11441107). In complex with TLR4, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion (PubMed:11441107, PubMed:20037584)

The "TLR6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TLR6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets